Literature DB >> 33910920

Neurodevelopmental outcomes at age 5 among children born preterm: EPIPAGE-2 cohort study.

Véronique Pierrat1,2, Laetitia Marchand-Martin3, Stéphane Marret4,5, Catherine Arnaud6,7,8, Valérie Benhammou3, Gilles Cambonie9, Thierry Debillon10,11, Marie-Noëlle Dufourg12, Catherine Gire13, François Goffinet3,14, Monique Kaminski3, Alexandre Lapillonne15, Andrei Scott Morgan3,16, Jean-Christophe Rozé17,18, Sabrina Twilhaar3, Marie-Aline Charles10,19, Pierre-Yves Ancel3,20.   

Abstract

OBJECTIVES: To describe neurodevelopment at age 5 among children born preterm.
DESIGN: Population based cohort study, EPIPAGE-2.
SETTING: France, 2011. PARTICIPANTS: 4441 children aged 5½ born at 24-26, 27-31, and 32-34 weeks MAIN OUTCOME MEASURES: Severe/moderate neurodevelopmental disabilities, defined as severe/moderate cerebral palsy (Gross Motor Function Classification System (GMFCS) ≥2), or unilateral or bilateral blindness or deafness, or full scale intelligence quotient less than minus two standard deviations (Wechsler Preschool and Primary Scale of Intelligence, 4th edition). Mild neurodevelopmental disabilities, defined as mild cerebral palsy (GMFCS-1), or visual disability ≥3.2/10 and <5/10, or hearing loss <40 dB, or full scale intelligence quotient (minus two to minus one standard deviation) or developmental coordination disorders (Movement Assessment Battery for Children, 2nd edition, total score less than or equal to the fifth centile), or behavioural difficulties (strengths and difficulties questionnaire, total score greater than or equal to the 90th centile), school assistance (mainstream class with support or special school), complex developmental interventions, and parents' concerns about development. The distributions of the scores in contemporary term born children were used as reference. Results are given after multiple imputation as percentages of outcome measures with exact binomial 95% confidence intervals.
RESULTS: Among 4441 participants, 3083 (69.4%) children were assessed. Rates of severe/moderate neurodevelopmental disabilities were 28% (95% confidence interval 23.4% to 32.2%), 19% (16.8% to 20.7%), and 12% (9.2% to 14.0%) and of mild disabilities were 38.5% (33.7% to 43.4%), 36% (33.4% to 38.1%), and 34% (30.2% to 37.4%) at 24-26, 27-31, and 32-34 weeks, respectively. Assistance at school was used by 27% (22.9% to 31.7%), 14% (12.1% to 15.9%), and 7% (4.4% to 9.0%) of children at 24-26, 27-31, and 32-34 weeks, respectively. About half of the children born at 24-26 weeks (52% (46.4% to 57.3%)) received at least one developmental intervention which decreased to 26% (21.8% to 29.4%) for those born at 32-34 weeks. Behaviour was the concern most commonly reported by parents. Rates of neurodevelopment disabilities increased as gestational age decreased and were higher in families with low socioeconomic status.
CONCLUSIONS: In this large cohort of children born preterm, rates of severe/moderate neurodevelopmental disabilities remained high in each gestational age group. Proportions of children receiving school assistance or complex developmental interventions might have a significant impact on educational and health organisations. Parental concerns about behaviour warrant attention. © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Year:  2021        PMID: 33910920     DOI: 10.1136/bmj.n741

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  26 in total

1.  Neurodevelopment at 5 Years of Age According to Early Screening for Patent Ductus Arteriosus in Extremely Preterm Infants.

Authors:  Gilles Cambonie; Jean-Christophe Rozé; Laetitia Marchand-Martin; Stéphane Marret; Xavier Durrmeyer; Héloïse Torchin; Pierre-Yves Ancel
Journal:  JAMA       Date:  2022-07-05       Impact factor: 157.335

Review 2.  Key role of Rho GTPases in motor disorders associated with neurodevelopmental pathologies.

Authors:  David I Anderson; Evelyne Bloch-Gallego
Journal:  Mol Psychiatry       Date:  2022-08-02       Impact factor: 13.437

3.  Urine podocyte mRNA loss in preterm infants and related perinatal risk factors.

Authors:  Qi Gao; Congchao Lu; Xiuying Tian; Jun Zheng; Fangrui Ding
Journal:  Pediatr Nephrol       Date:  2022-06-27       Impact factor: 3.714

4.  Population birth outcomes in 2020 and experiences of expectant mothers during the COVID-19 pandemic: A 'born in Wales' mixed methods study using routine data.

Authors:  Hope Jones; Mike Seaborne; Laura Cowley; David Odd; Shantini Paranjothy; Ashley Akbari; Sinead Brophy
Journal:  PLoS One       Date:  2022-05-24       Impact factor: 3.752

5.  Effects of Early Motor Interventions on Gross Motor and Locomotor Development for Infants at-Risk of Motor Delay: A Systematic Review.

Authors:  Marie-Victorine Dumuids-Vernet; Joëlle Provasi; David Ian Anderson; Marianne Barbu-Roth
Journal:  Front Pediatr       Date:  2022-04-28       Impact factor: 3.569

6.  Preterm birth and the risk of chronic disease multimorbidity in adolescence and early adulthood: A population-based cohort study.

Authors:  Katriina Heikkilä; Anna Pulakka; Johanna Metsälä; Suvi Alenius; Petteri Hovi; Mika Gissler; Sven Sandin; Eero Kajantie
Journal:  PLoS One       Date:  2021-12-31       Impact factor: 3.240

7.  Management and outcomes of extreme preterm birth.

Authors:  Andrei S Morgan; Marina Mendonça; Nicole Thiele; Anna L David
Journal:  BMJ       Date:  2022-01-10

8.  A Potential ceRNA Network for Neurological Damage in Preterm Infants.

Authors:  Jin Huang; Xuejing Liang; Zhenyu Cai
Journal:  Biomed Res Int       Date:  2021-08-21       Impact factor: 3.411

9.  Postnatal age is strongly correlated with the early development of the gut microbiome in preterm infants.

Authors:  Wei Shen; Wen Qiu; Yuting Liu; Weihua Liao; Yiyi Ma; Yan He; Zhang Wang; Hongwei Zhou
Journal:  Transl Pediatr       Date:  2021-09

10.  Global prevalence of long-term neurodevelopmental impairment following extremely preterm birth: a systematic literature review.

Authors:  Sujata P Sarda; Grammati Sarri; Csaba Siffel
Journal:  J Int Med Res       Date:  2021-07       Impact factor: 1.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.